Usefulness of sennoside as an agent for mechanical bowel preparation prior to elective colon cancer surgery.
OBJECTIVE
We retrospectively evaluated the usefulness of sennoside as an agent for mechanical bowel preparation prior to elective colon cancer surgery.


METHODS
A total of 86 patients were given 12 mg of sennoside on the evening prior to resective surgery for colon cancer, followed by intravenous antimicrobial prophylaxis used on the day of surgery or until postoperative day 2.


RESULTS
The incidence of surgical site infection in the study group was 4.7%, which was comparable to that in the historical control patients (3.5%, p>0.99), who had received polyethylene glycol for mechanical bowel preparation prior to colon surgery. On multivariate logistic regression analysis, only body mass index (p=0.04) was an independent significant factor affecting the surgical site infection. The intraoperative spillage was not influenced by the presence of stenosis, although the amount of fecal matter was higher in the upstream colon segment (p<0.01) and downstream segment (p=0.07) in patients with a stenotic lesion occupying more than two-thirds of the lumen (n=29) than in those without such severe stenosis (n=57).


CONCLUSIONS
Sennoside seems to be an acceptable agent for mechanical bowel preparation even in patients with stenosis.
Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan. k_ishi@saitama-med.ac.jp
Keiichiro
K
Ishibashi
Kensuke
K
Kumamoto
Kouki
K
Kuwabara
Naoko
N
Hokama
Toru
T
Ishiguro
Tomonori
T
Ohsawa
Norimichi
N
Okada
Tatsuya
T
Miyazaki
Masaru
M
Yokoyama
Yoshitaka
Y
Tsuji
Norihiro
N
Haga
Hideyuki
H
Ishida
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000880:Anthraquinones / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis; D002400:Cathartics / Q000008:administration & dosage*; D015311:Cefmetazole / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000601:surgery*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004917:Erythromycin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015994:Incidence; D007612:Kanamycin / Q000627:therapeutic use; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011300:Preoperative Care / Q000379:methods*; D012189:Retrospective Studies; D012676:Senna Extract; D000081226:Sennosides; D013530:Surgical Wound Infection / Q000453:epidemiology / Q000517:prevention & control*; D016896:Treatment Outcome
D000880:Anthraquinones; D000900:Anti-Bacterial Agents; D002400:Cathartics; D000081226:Sennosides; D015311:Cefmetazole; D007612:Kanamycin; D004917:Erythromycin; D012676:Senna Extract